Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LUNG CANCER LIQUID BIOPSY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL LUNG CANCER LIQUID BIOPSY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEOMOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 PATENT ANALYSIS
5.4 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 INCIDENCE AND PREVALENCE OF LUNG CANCER
6.1.1 REGIONAL
6.1.2 COUNTRY
6.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 DIAGNOSIS RATE BY MATURED MARKETS
7.5 INTERVIEWS WITH MANUFACTURING COMPANIES
7.6 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY PRODUCT
9.1 OVERVIEW
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB SEGMENTS)
9.2 INSTRUMENTS
9.2.1 BY TYPE
9.2.1.1. CONVENTIONAL PCR
9.2.1.2. REAL-TIME RT-PCR
9.2.1.3. DIGITAL PCR
9.2.1.4. MICROCSOPE
9.2.1.5. ULTRACENTRIFUGATION MACHINE
9.2.1.6. MICROPLATE READER
9.2.1.7. OTHERS
9.2.2 BY MODALITY
9.2.2.1. FIXED
9.2.2.2. MOBILE
9.2.3 BY USAGE
9.2.3.1. MANUAL
9.2.3.2. AUTOMATIC
9.2.3.3. SEMI-AUTOMATIC
9.3 KITS AND CONSUMBALES
9.3.1 KITS
9.3.1.1. BLOOD DNA EXTRACTION KIT
9.3.1.2. CELL-FREE TOTAL NUCLEIC ACID ISOLATION KIT
9.3.1.3. CELL-FREE DNA ISOLATION KIT
9.3.1.4. TISSUE DNA EXTRACTION KIT
9.3.1.5. ANTIBODY KIT
9.3.1.6. METHYLATED GENES KIT
9.3.2 CALL FREE DNA COLLECTION TUBE
9.3.3 RNA COLLECTION TUBE
9.3.4 SAMPLE PREPARATION CONSUMABLES
9.3.5 DNA FRAGMENTATION & AMPLIFICATION
9.3.6 LIBRARY PREPARATION & TARGET ENRICHMENT
9.3.7 QUALITY CONTROL
9.3.8 OTHER CONSUMABLES
9.4 SERVICES
10 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY BIOMARKER
10.1 OVERVIEW
10.2 CIRCULATING TUMOR CELL
10.2.1 IMMUNE ENRICHMENT METHOD
10.2.1.1. IMMUNOMAGNETIC BEAD METHOD
10.2.1.1.1. POSITIVE-ENRICHMENT METHOD
10.2.1.1.2. NEGATIVE-ENRICHMENT METHOD
10.2.1.2. IMMUNOADSORPTION METHOD
10.2.2 PHYSICAL ENRICHMENT METHOD
10.3 CIRCULATING TUMOR DNA
10.3.1 NEXT GENERATION SEQUENCING
10.3.2 REAL TIME PCR
10.3.3 DIGITAL DROPLET PCR
10.3.4 SCORPION AMPLIFICATION REFRACTORY MUTATION SYSTEMS
10.3.5 PEPTIDE NUCLEIC ACID‐LOCKED NUCLEIC ACID PCR
10.4 MICRO RNA
10.4.1 RNA SEQUENCENCING
10.4.2 MICROARRAYS
10.4.3 REAL TIME PCR
10.5 TUMOR-EDUCATED PLATELETS
10.5.1 ULTRA-DEEP
10.5.2 MASSIVE PARALLEL
10.5.3 LONG-READ SEQUENCING
10.6 TUMOUR DERIVED EXOSOMES
10.6.1 EV ARRAY
10.6.2 IMMUNOAFFINITY‐BASED TECHNIQUESULTRACENTRIFUGATION
10.6.2.1. ELISA
10.6.2.2. WESTERN BLOT
10.6.3 DENSITY GRADIENT
10.6.4 MICROFLUIDICS‐BASED
10.6.5 NANOTECHNOLOGY
10.6.6 OTHERS
11 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY SAMPLE
11.1 OVERVIEW
11.2 BLOOD
11.3 URINE
11.4 SALIVA
11.5 PLEURAL FLUID
11.6 CEREBRAL SPINAL FLUID
12 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY STAGES
12.1 OVERVIEW
12.2 STAGE 0
12.3 STAGE I
12.4 STAGE II
12.5 STAGE III
12.6 STAGE IV
13 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY AGE
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
14 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY TYPE
14.1 OVERVIEW
14.2 SMALL CELL LUNG CANCER
14.2.1 CIRCULATING TUMOR CELL
14.2.1.1. IMMUNE ENRICHMENT METHOD
14.2.1.1.1. IMMUNOMAGNETIC BEAD METHOD
14.2.1.1.1.1 POSITIVE-ENRICHMENT METHOD
14.2.1.1.1.2 NEGATIVE-ENRICHMENT METHOD
14.2.1.1.2. IMMUNOADSORPTION METHOD
14.2.1.2. PHYSICAL ENRICHMENT METHOD
14.2.2 CIRCULATING TUMOR DNA
14.2.2.1. NEXT GENERATION SEQUENCING
14.2.2.2. REAL TIME PCR
14.2.2.3. DIGITAL DROPLET PCR
14.2.2.4. SCORPION AMPLIFICATION REFRACTORY MUTATION SYSTEMS
14.2.2.5. PEPTIDE NUCLEIC ACID‐LOCKED NUCLEIC ACID PCR
14.2.3 MICRO RNA
14.2.3.1. RNA SEQUENCENCING
14.2.3.2. MICROARRAYS
14.2.3.3. REAL TIME PCR
14.2.4 TUMOR-EDUCATED PLATELETS
14.2.4.1. ULTRA-DEEP
14.2.4.2. MASSIVE PARALLEL
14.2.4.3. LONG-READ SEQUENCING
14.2.5 TUMOUR DERIVED EXOSOMES
14.2.5.1. EV ARRAY
14.2.5.2. IMMUNOAFFINITY‐BASED TECHNIQUESULTRACENTRIFUGATION
14.2.5.2.1. ELISA
14.2.5.2.2. WESTERN BLOT
14.2.5.3. DENSITY GRADIENT
14.2.5.4. MICROFLUIDICS‐BASED
14.2.5.5. NANOTECHNOLOGY
14.2.5.6. OTHERS
14.3 NON SMALL CELL LUNG CANCER (NSCLC)
14.3.1 CIRCULATING TUMOR CELL
14.3.1.1. IMMUNE ENRICHMENT METHOD
14.3.1.1.1. IMMUNOMAGNETIC BEAD METHOD
14.3.1.1.1.1 POSITIVE-ENRICHMENT METHOD
14.3.1.1.1.2 NEGATIVE-ENRICHMENT METHOD
14.3.1.1.2. IMMUNOADSORPTION METHOD
14.3.1.2. PHYSICAL ENRICHMENT METHOD
14.3.2 CIRCULATING TUMOR DNA
14.3.2.1. NEXT GENERATION SEQUENCING
14.3.2.2. REAL TIME PCR
14.3.2.3. DIGITAL DROPLET PCR
14.3.2.4. SCORPION AMPLIFICATION REFRACTORY MUTATION SYSTEMS
14.3.2.5. PEPTIDE NUCLEIC ACID‐LOCKED NUCLEIC ACID PCR
14.3.3 MICRO RNA
14.3.3.1. RNA SEQUENCENCING
14.3.3.2. MICROARRAYS
14.3.3.3. REAL TIME PCR
14.3.4 TUMOR-EDUCATED PLATELETS
14.3.4.1. ULTRA-DEEP
14.3.4.2. MASSIVE PARALLEL
14.3.4.3. LONG-READ SEQUENCING
14.3.5 TUMOUR DERIVED EXOSOMES
14.3.5.1. EV ARRAY
14.3.5.2. IMMUNOAFFINITY‐BASED TECHNIQUESULTRACENTRIFUGATION
14.3.5.2.1. ELISA
14.3.5.2.2. WESTERN BLOT
14.3.5.3. DENSITY GRADIENT
14.3.5.4. MICROFLUIDICS‐BASED
14.3.5.5. NANOTECHNOLOGY
14.3.5.6. OTHERS
15 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 ASSOCIATED LABS
15.4 INDEPENDENT DIAGNOSTIC LABORATORIES
15.5 DIAGNOSTIC IMAGING CENTERS
15.6 CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY REGION
17.1 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 U.K.
17.3.3 ITALY
17.3.4 FRANCE
17.3.5 SPAIN
17.3.6 RUSSIA
17.3.7 SWITZERLAND
17.3.8 TURKEY
17.3.9 BELGIUM
17.3.10 NETHERLANDS
17.3.11 DENMARK
17.3.12 SWEDEN
17.3.13 POLAND
17.3.14 NORWAY
17.3.15 FINLAND
17.3.16 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 SINGAPORE
17.4.6 THAILAND
17.4.7 INDONESIA
17.4.8 MALAYSIA
17.4.9 PHILIPPINES
17.4.10 AUSTRALIA
17.4.11 NEW ZEALAND
17.4.12 VIETNAM
17.4.13 TAIWAN
17.4.14 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRAZIL
17.5.2 ARGENTINA
17.5.3 REST OF SOUTH AMERICA
17.6 MIDDLE EAST AND AFRICA
17.6.1 SOUTH AFRICA
17.6.2 EGYPT
17.6.3 BAHRAIN
17.6.4 UNITED ARAB EMIRATES
17.6.5 KUWAIT
17.6.6 OMAN
17.6.7 QATAR
17.6.8 SAUDI ARABIA
17.6.9 REST OF MIDDLE EAST AND AFRICA
17.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, COMPANY PROFILE
19.1 BIOCOMPARE
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 HORIZON DISCOVERY LTD.
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPEMENTS
19.3 F. HOFFMANN-LA ROCHE LTD
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPEMENTS
19.4 QIAGEN
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPEMENTS
19.5 AGENA BIOSCIENCE, INC.
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPEMENTS
19.6 4BASECARE.
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPEMENTS
19.7 BIONOVITUS, LLC.
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPEMENTS
19.8 BIOCARTIS NV
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPEMENTS
19.9 EPIGENOMICS AG
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPEMENTS
19.1 LUNGLIFE AI, INC.
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPEMENTS
19.11 PERSONAL GENOME DIAGNOSTICS INC.
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPEMENTS
19.12 MEDGENOME
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPEMENTS
19.13 SYSMEX EUROPE SE
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPEMENTS
19.14 THERMO FISHER SCIENTIFIC INC.
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPEMENTS
19.15 STILLA
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPEMENTS
19.16 INIVATA LTD
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPEMENTS
19.17 ALIGENT
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPEMENTS
19.18 CELLCARTA
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPEMENTS
19.19 NEOGENOMICS LABORATORIES.
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPEMENTS
19.2 BOREAL GENOMICS INC.
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPEMENTS
19.21 BIO-RAD LABORATORIES, INC.
19.21.1 COMPANY OVERVIEW
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHIC PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPEMENTS
19.22 SAGA DIAGNOSTICS
19.22.1 COMPANY OVERVIEW
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHIC PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPEMENTS
19.23 SERACARE
19.23.1 COMPANY OVERVIEW
19.23.2 REVENUE ANALYSIS
19.23.3 GEOGRAPHIC PRESENCE
19.23.4 PRODUCT PORTFOLIO
19.23.5 RECENT DEVELOPEMENTS
19.24 ILLUMINA, INC.
19.24.1 COMPANY OVERVIEW
19.24.2 REVENUE ANALYSIS
19.24.3 GEOGRAPHIC PRESENCE
19.24.4 PRODUCT PORTFOLIO
19.24.5 RECENT DEVELOPEMENTS
19.25 MENARINI SILICON BIOSYSTEMS
19.25.1 COMPANY OVERVIEW
19.25.2 REVENUE ANALYSIS
19.25.3 GEOGRAPHIC PRESENCE
19.25.4 PRODUCT PORTFOLIO
19.25.5 RECENT DEVELOPEMENTS
19.26 BIOMARK DIAGNOSTICS INC.
19.26.1 COMPANY OVERVIEW
19.26.2 REVENUE ANALYSIS
19.26.3 GEOGRAPHIC PRESENCE
19.26.4 PRODUCT PORTFOLIO
19.26.5 RECENT DEVELOPEMENTS
19.27 LUCENCE HEALTH INC.
19.27.1 COMPANY OVERVIEW
19.27.2 REVENUE ANALYSIS
19.27.3 GEOGRAPHIC PRESENCE
19.27.4 PRODUCT PORTFOLIO
19.27.5 RECENT DEVELOPEMENTS
19.28 QUEST DIAGNOSTICS INCORPORATED.
19.28.1 COMPANY OVERVIEW
19.28.2 REVENUE ANALYSIS
19.28.3 GEOGRAPHIC PRESENCE
19.28.4 PRODUCT PORTFOLIO
19.28.5 RECENT DEVELOPEMENTS
19.29 ELEMENT BIOSCIENCES
19.29.1 COMPANY OVERVIEW
19.29.2 REVENUE ANALYSIS
19.29.3 GEOGRAPHIC PRESENCE
19.29.4 PRODUCT PORTFOLIO
19.29.5 RECENT DEVELOPEMENTS
19.3 VORTEX BIOSCIENCES
19.30.1 COMPANY OVERVIEW
19.30.2 REVENUE ANALYSIS
19.30.3 GEOGRAPHIC PRESENCE
19.30.4 PRODUCT PORTFOLIO
19.30.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
